CYP1B1 and neoplasm: Although compound 16 was not enriched in the top-ranked predicted pathways identified by KEGG analysis in this study, its predicted targets such as TNF, ALOX5, PTGS2, CYP1B1 were associated with inflammation, lipid metabolism, and drug resistance, suggesting potential anti-tumour effects possibly through non-classical pathways.